NASDAQ:VCEL Vericel (VCEL) Stock Price, News & Analysis $31.79 +1.56 (+5.16%) Closing price 04:00 PM EasternExtended Trading$31.82 +0.03 (+0.09%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vericel Stock (NASDAQ:VCEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vericel alerts:Sign Up Key Stats Today's Range$29.88▼$32.0550-Day Range$29.84▼$41.4552-Week Range$29.24▼$63.00Volume1.21 million shsAverage Volume926,935 shsMarket Capitalization$1.60 billionP/E Ratio264.94Dividend YieldN/APrice Target$60.40Consensus RatingModerate Buy Company Overview Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues. Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients. EPICEL® (cultured epidermal autograft) is approved for use in pediatric burn patients with deep partial-thickness or full-thickness burns covering at least 30% of total body surface area. Vericel manages the entire manufacturing process—from cell collection and expansion to final product release—at its state-of-the-art cell processing facilities in the United States. The company distributes its products across the U.S. market and has established licensing and distribution partnerships to serve patients in select international regions, including Europe, Canada and Australia. Beyond its commercial portfolio, Vericel maintains a pipeline of investigational therapies targeting tendon repair and other musculoskeletal injuries. Its research and development efforts leverage proprietary cell culture platforms and delivery technologies aimed at addressing significant unmet medical needs in regenerative medicine.AI Generated. May Contain Errors. Read More Vericel Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreVCEL MarketRank™: Vericel scored higher than 55% of companies evaluated by MarketBeat, and ranked 490th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingVericel has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialVericel has a consensus price target of $60.40, representing about 90.0% upside from its current price of $31.79.Amount of Analyst CoverageVericel has only been the subject of 2 research reports in the past 90 days.Read more about Vericel's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth214.29% Earnings GrowthEarnings for Vericel are expected to grow by 214.29% in the coming year, from $0.14 to $0.44 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is 264.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.43.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is 264.94, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 75.67.Price to Book Value per Share RatioVericel has a P/B Ratio of 5.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vericel's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.50% of the float of Vericel has been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Vericel has recently decreased by 2.31%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.50% of the float of Vericel has been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Vericel has recently decreased by 2.31%, indicating that investor sentiment is improving. News and Social Media1.7 / 5News Sentiment1.05 News SentimentVericel has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Vericel this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for VCEL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Vericel to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.20% of the stock of Vericel is held by insiders.Read more about Vericel's insider trading history. Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VCEL Stock News HeadlinesCanaccord Genuity Keeps Their Buy Rating on Vericel (VCEL)September 26 at 8:02 PM | theglobeandmail.comVericel (NASDAQ:VCEL) Hits New 52-Week Low Following Analyst DowngradeSeptember 19, 2025 | americanbankingnews.comYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.September 29 at 2:00 AM | Priority Gold (Ad)Vericel (NASDAQ:VCEL) Shares Gap Down Following Analyst DowngradeSeptember 19, 2025 | americanbankingnews.comDeclining Stock and Decent Financials: Is The Market Wrong About Vericel Corporation (NASDAQ:VCEL)?September 18, 2025 | finance.yahoo.comVericel downgraded to Neutral from Buy at BTIGSeptember 17, 2025 | msn.comBTIG Downgrades Vericel (VCEL)September 17, 2025 | msn.comHere’s Why Vericel Corp. (VCEL) Traded Down in Q2September 12, 2025 | msn.comSee More Headlines VCEL Stock Analysis - Frequently Asked Questions How have VCEL shares performed this year? Vericel's stock was trading at $54.91 at the beginning of the year. Since then, VCEL shares have decreased by 42.1% and is now trading at $31.79. How were Vericel's earnings last quarter? Vericel Corporation (NASDAQ:VCEL) posted its quarterly earnings data on Thursday, July, 31st. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.03. The company's quarterly revenue was up 20.1% on a year-over-year basis. Read the conference call transcript. How do I buy shares of Vericel? Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vericel investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Palo Alto Networks (PANW) and Netflix (NFLX). Company Calendar Last Earnings7/31/2025Today9/29/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VCEL CIK887359 Webwww.vcel.com Phone(617) 588-5555Fax617-588-5554Employees300Year Founded1989Price Target and Rating Average Price Target for Vericel$60.40 High Price Target$67.00 Low Price Target$51.00 Potential Upside/Downside+90.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.12 Trailing P/E Ratio264.94 Forward P/E Ratio227.07 P/E GrowthN/ANet Income$10.36 million Net Margins2.85% Pretax Margin2.91% Return on Equity2.47% Return on Assets1.69% Debt Debt-to-Equity RatioN/A Current Ratio4.97 Quick Ratio4.56 Sales & Book Value Annual Sales$237.22 million Price / Sales6.76 Cash Flow$0.33 per share Price / Cash Flow96.74 Book Value$5.92 per share Price / Book5.37Miscellaneous Outstanding Shares50,460,000Free Float46,827,000Market Cap$1.60 billion OptionableOptionable Beta1.33 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:VCEL) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.